| Q34203368 | A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia |
| Q55161186 | A systematic literature review of the clinical and health economic burden of schizophrenia in privately insured patients in the United States. |
| Q47998008 | Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics |
| Q37333252 | Burden of treatment for chronic illness: a concept analysis and review of the literature. |
| Q26774170 | Can the Direct Medical Cost of Chronic Disease Be Transferred across Different Countries? Using Cost-of-Illness Studies on Type 2 Diabetes, Epilepsy and Schizophrenia as Examples |
| Q55324826 | Claims-based proxies of patient instability among commercially insured adults with schizophrenia. |
| Q41312111 | Common variants of HTR1A and SLC6A4 confer the increasing risk of Schizophrenia susceptibility: A population-based association and epistasis analysis |
| Q58763260 | Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis |
| Q41396429 | Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics |
| Q36752637 | Conserved functional connectivity but impaired effective connectivity of thalamocortical circuitry in schizophrenia |
| Q38692993 | Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain |
| Q35186007 | Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia |
| Q36445106 | Estimated economic benefits from low-frequency administration of atypical antipsychotics in treatment of schizophrenia: a decision model |
| Q47779788 | Factors in Maintaining a Stable Patient-Physician Relationship among Individuals with Schizophrenia. |
| Q35427820 | Health care resource use and direct medical costs for patients with schizophrenia in Tianjin, People's Republic of China |
| Q34982167 | Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis |
| Q24193953 | Information and communication technology based prompting for treatment compliance for people with serious mental illness |
| Q24202535 | Information and communication technology based prompting for treatment compliance for people with serious mental illness |
| Q64096968 | Predicting hospital-acquired pneumonia among schizophrenic patients: a machine learning approach |
| Q47902183 | Predictors for clinical deterioration of mental state in patients assessed by telephone-based mental health triage |
| Q36139891 | Probing thalamic integrity in schizophrenia using concurrent transcranial magnetic stimulation and functional magnetic resonance imaging |
| Q33652933 | Resource utilization and cost in a commercially insured population with schizophrenia |
| Q38191701 | Review of international early psychosis programmes and a model to overcome unique challenges to the treatment of early psychosis in the United States |
| Q39387296 | Rural and remote early psychosis intervention services: the Gordian knot of early intervention |
| Q52587739 | Sodium nitroprusside is effective in preventing and/or reversing the development of schizophrenia-related behaviors in an animal model: The SHR strain. |
| Q35249595 | Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database |
| Q38769604 | The Cost of Relapse in Schizophrenia. |
| Q35886546 | The ethics of elective psychopharmacology |
| Q35948848 | Treatment response, safety, and tolerability of paliperidone extended release treatment in patients recently diagnosed with schizophrenia |
| Q38842576 | Twelve-Month Health Care Use and Mortality in Commercially Insured Young People With Incident Psychosis in the United States |